Trade Regeneron Pharmaceuticals, Inc. - REGN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.96 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.025457% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003235% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Regeneron Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Key Stats
| Prev. Close* | 724.73 |
| Open* | 719.68 |
| 1-Year Change* | 4.13% |
| Day's Range* | 719.4 - 724.25 |
| 52 wk Range | 538.01-837.55 |
| Average Volume (10 days) | 526.40K |
| Average Volume (3 months) | 12.32M |
| Market Cap | 79.55B |
| P/E Ratio | 19.70 |
| Shares Outstanding | 109.71M |
| Revenue | 12.37B |
| EPS | 36.80 |
| Dividend (Yield %) | N/A |
| Beta | 0.23 |
| Next Earnings Date | Aug 1, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 26, 2023 | 724.16 | 6.53 | 0.91% | 717.63 | 725.78 | 714.89 |
| May 25, 2023 | 724.73 | -1.54 | -0.21% | 726.27 | 735.68 | 720.88 |
| May 24, 2023 | 736.33 | -8.07 | -1.08% | 744.40 | 749.62 | 733.81 |
| May 23, 2023 | 748.25 | 2.25 | 0.30% | 746.00 | 756.01 | 742.38 |
| May 22, 2023 | 751.11 | -2.46 | -0.33% | 753.57 | 767.37 | 741.84 |
| May 19, 2023 | 758.77 | 8.95 | 1.19% | 749.82 | 763.46 | 748.95 |
| May 18, 2023 | 746.56 | 7.53 | 1.02% | 739.03 | 748.87 | 738.93 |
| May 17, 2023 | 749.39 | 12.94 | 1.76% | 736.45 | 750.67 | 731.31 |
| May 16, 2023 | 741.89 | -1.04 | -0.14% | 742.93 | 745.74 | 737.76 |
| May 15, 2023 | 750.02 | 7.19 | 0.97% | 742.83 | 751.68 | 737.22 |
| May 12, 2023 | 743.62 | -2.36 | -0.32% | 745.98 | 751.60 | 738.44 |
| May 11, 2023 | 744.86 | 0.35 | 0.05% | 744.51 | 748.90 | 739.33 |
| May 10, 2023 | 748.70 | 0.93 | 0.12% | 747.77 | 754.71 | 745.53 |
| May 9, 2023 | 754.26 | 3.63 | 0.48% | 750.63 | 756.40 | 744.25 |
| May 8, 2023 | 749.96 | -4.79 | -0.63% | 754.75 | 758.99 | 745.28 |
| May 5, 2023 | 758.58 | 4.35 | 0.58% | 754.23 | 768.25 | 741.55 |
| May 4, 2023 | 751.10 | -18.48 | -2.40% | 769.58 | 774.09 | 743.44 |
| May 3, 2023 | 800.80 | -2.06 | -0.26% | 802.86 | 812.34 | 789.70 |
| May 2, 2023 | 798.08 | -2.45 | -0.31% | 800.53 | 814.72 | 795.39 |
| May 1, 2023 | 805.79 | 6.91 | 0.86% | 798.88 | 811.12 | 798.88 |
Regeneron Pharmaceuticals, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Tuesday, May 30, 2023 | ||
| Time (UTC) 16:30 | Country US
| Event Regeneron Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Regeneron Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual)Forecast -Previous - |
| Wednesday, June 7, 2023 | ||
| Time (UTC) 12:30 | Country US
| Event Regeneron Pharmaceuticals Inc at Jefferies Healthcare Conference Regeneron Pharmaceuticals Inc at Jefferies Healthcare ConferenceForecast -Previous - |
| Friday, June 9, 2023 | ||
| Time (UTC) 14:30 | Country US
| Event Regeneron Pharmaceuticals Inc Annual Shareholders Meeting Regeneron Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, June 14, 2023 | ||
| Time (UTC) 15:40 | Country US
| Event Regeneron Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Regeneron Pharmaceuticals Inc at Goldman Sachs Healthcare ConferenceForecast -Previous - |
| Tuesday, August 1, 2023 | ||
| Time (UTC) 12:30 | Country US
| Event Q2 2023 Regeneron Pharmaceuticals Inc Earnings Release Q2 2023 Regeneron Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Wednesday, November 1, 2023 | ||
| Time (UTC) 12:30 | Country US
| Event Q3 2023 Regeneron Pharmaceuticals Inc Earnings Release Q3 2023 Regeneron Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 12172.9 | 16071.7 | 8497.1 | 7863.4 | 6710.8 |
| Revenue | 12172.9 | 16071.7 | 8497.1 | 7863.4 | 6710.8 |
| Cost of Revenue, Total | 1560.4 | 2437.5 | 1119.9 | 782.2 | 434.1 |
| Gross Profit | 10612.5 | 13634.2 | 7377.2 | 7081.2 | 6276.7 |
| Total Operating Expense | 7434 | 7124.9 | 4920.5 | 5653.6 | 4176.4 |
| Selling/General/Admin. Expenses, Total | 2115.9 | 1824.9 | 1346 | 1834.8 | 1556.2 |
| Research & Development | 3592.5 | 2908.1 | 2735 | 3036.6 | 2186.1 |
| Operating Income | 4738.9 | 8946.8 | 3576.6 | 2209.8 | 2534.4 |
| Interest Income (Expense), Net Non-Operating | -19.6 | 328.8 | 139.1 | 88.1 | 13.7 |
| Other, Net | 139.5 | 50.2 | 94.7 | 131.2 | 5.4 |
| Net Income Before Taxes | 4858.8 | 9325.8 | 3810.4 | 2429.1 | 2553.5 |
| Net Income After Taxes | 4338.4 | 8075.3 | 3513.2 | 2115.8 | 2376.4 |
| Net Income Before Extra. Items | 4338.4 | 8075.3 | 3513.2 | 2115.8 | 2376.4 |
| Net Income | 4338.4 | 8075.3 | 3513.2 | 2115.8 | 2444.4 |
| Income Available to Common Excl. Extra. Items | 4338.4 | 8075.3 | 3513.2 | 2115.8 | 2376.4 |
| Income Available to Common Incl. Extra. Items | 4338.4 | 8075.3 | 3513.2 | 2115.8 | 2444.4 |
| Dilution Adjustment | |||||
| Diluted Net Income | 4338.4 | 8075.3 | 3513.2 | 2115.8 | 2444.4 |
| Diluted Weighted Average Shares | 113.5 | 112.2 | 115.1 | 114.6 | 114.8 |
| Diluted EPS Excluding Extraordinary Items | 38.2238 | 71.9724 | 30.523 | 18.4625 | 20.7003 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | 40.4714 | 71.9724 | 30.523 | 18.4625 | 20.7003 |
| Total Extraordinary Items | 68 | ||||
| Other Operating Expenses, Total | -89.9 | -45.6 | -280.4 | ||
| Unusual Expense (Income) | 255.1 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total revenue | 3162.1 | 3414.4 | 2936.2 | 2857.2 | 2965.1 |
| Revenue | 3162.1 | 3414.4 | 2936.2 | 2857.2 | 2965.1 |
| Cost of Revenue, Total | 457.5 | 540.6 | 317.8 | 297.1 | 404.9 |
| Gross Profit | 2704.6 | 2873.8 | 2618.4 | 2560.1 | 2560.2 |
| Total Operating Expense | 2215.4 | 2267.6 | 1712.5 | 1747.3 | 1706.6 |
| Selling/General/Admin. Expenses, Total | 601.1 | 660.5 | 529.1 | 476.3 | 450 |
| Research & Development | 1101.2 | 1043.1 | 911.3 | 794.3 | 843.8 |
| Other Operating Expenses, Total | -0.5 | -6.6 | -45.7 | -17.4 | -20.2 |
| Operating Income | 946.7 | 1146.8 | 1223.7 | 1109.9 | 1258.5 |
| Interest Income (Expense), Net Non-Operating | -87.5 | 143 | 239 | -176.8 | -224.8 |
| Other, Net | -1.2 | 34.9 | 47.1 | 30.1 | 27.4 |
| Net Income Before Taxes | 858 | 1324.7 | 1509.8 | 963.2 | 1061.1 |
| Net Income After Taxes | 817.8 | 1197.1 | 1315.7 | 852.1 | 973.5 |
| Net Income Before Extra. Items | 817.8 | 1197.1 | 1315.7 | 852.1 | 973.5 |
| Net Income | 817.8 | 1197.1 | 1315.7 | 852.1 | 973.5 |
| Income Available to Common Excl. Extra. Items | 817.8 | 1197.1 | 1315.7 | 852.1 | 973.5 |
| Income Available to Common Incl. Extra. Items | 817.8 | 1197.1 | 1315.7 | 852.1 | 973.5 |
| Diluted Net Income | 817.8 | 1197.1 | 1315.7 | 852.1 | 973.5 |
| Diluted Weighted Average Shares | 114 | 114.1 | 112.8 | 114 | 113.1 |
| Diluted EPS Excluding Extraordinary Items | 7.17368 | 10.4917 | 11.664 | 7.47456 | 8.60743 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | 7.66579 | 10.7546 | 11.664 | 9.20263 | 8.85588 |
| Unusual Expense (Income) | 56.1 | 30 | 0 | 197 | 28.1 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 15884.1 | 14014.9 | 9779.1 | 7689.1 | 6447.6 |
| Cash and Short Term Investments | 7742.3 | 5694.7 | 3587 | 3214.3 | 2809.9 |
| Cash & Equivalents | 3105.9 | 2885.6 | 2193.7 | 1617.8 | 1467.7 |
| Short Term Investments | 4636.4 | 2809.1 | 1393.3 | 1596.5 | 1342.2 |
| Total Receivables, Net | 5328.7 | 6036.5 | 4114.7 | 2672.2 | 2243.2 |
| Accounts Receivable - Trade, Net | 5328.7 | 6036.5 | 4114.7 | 2672.2 | 2243.2 |
| Total Inventory | 2401.9 | 1951.3 | 1916.6 | 1415.5 | 1151.2 |
| Prepaid Expenses | 411.2 | 332.4 | 160.8 | 387.1 | 243.3 |
| Other Current Assets, Total | |||||
| Total Assets | 29214.5 | 25434.8 | 17163.3 | 14805.2 | 11734.5 |
| Property/Plant/Equipment, Total - Net | 3763 | 3482.2 | 3221.6 | 2890.4 | 2575.8 |
| Property/Plant/Equipment, Total - Gross | 5432.2 | 4880.3 | 4352.7 | 3812.8 | 3304.5 |
| Accumulated Depreciation, Total | -1669.2 | -1398.1 | -1131.1 | -922.4 | -728.7 |
| Long Term Investments | 6640.1 | 6878 | 3194.8 | 3312.4 | 1800.5 |
| Other Long Term Assets, Total | 2011.8 | 1059.7 | 967.8 | 913.3 | 910.6 |
| Total Current Liabilities | 3141.3 | 3932.5 | 2697.4 | 2096.6 | 1442.8 |
| Accounts Payable | 589.2 | 564 | 475.5 | 418.1 | 218.2 |
| Accrued Expenses | 2073.9 | 1880.5 | 1502.3 | 1037.4 | 751.3 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 719.7 | |||
| Other Current Liabilities, Total | 478.2 | 768.3 | 719.6 | 641.1 | 473.3 |
| Total Liabilities | 6550.5 | 6666 | 6138 | 3715.5 | 2977.2 |
| Total Long Term Debt | 2701.4 | 1980 | 2695.7 | 713.9 | 708.5 |
| Capital Lease Obligations | 720 | 0 | 717.2 | 713.9 | 708.5 |
| Other Liabilities, Total | 707.8 | 753.5 | 744.9 | 905 | 825.9 |
| Total Equity | 22664 | 18768.8 | 11025.3 | 11089.7 | 8757.3 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Additional Paid-In Capital | 9949.3 | 8087.5 | 6716.2 | 4428.6 | 3911.6 |
| Retained Earnings (Accumulated Deficit) | 23306.7 | 18968.3 | 10893 | 7379.8 | 5254.3 |
| Treasury Stock - Common | -10353.3 | -8260.9 | -6613.3 | -739.9 | -396.4 |
| Other Equity, Total | -238.8 | -26.2 | 29.3 | 21.1 | -12.3 |
| Total Liabilities & Shareholders’ Equity | 29214.5 | 25434.8 | 17163.3 | 14805.2 | 11734.5 |
| Total Common Shares Outstanding | 109.6 | 108.675 | 106.951 | 110.277 | 109.006 |
| Long Term Debt | 1981.4 | 1980 | 1978.5 | ||
| Intangibles, Net | 915.5 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 16909.2 | 15884.1 | 15428.6 | 15529.9 | 14306 |
| Cash and Short Term Investments | 8959.7 | 7742.3 | 7021.7 | 7566.4 | 7050.6 |
| Cash & Equivalents | 3916.3 | 3105.9 | 3491.3 | 3395.1 | 3345.7 |
| Short Term Investments | 5043.4 | 4636.4 | 3530.4 | 4171.3 | 3704.9 |
| Total Receivables, Net | 5118.6 | 5328.7 | 5548.3 | 5161.4 | 4839 |
| Accounts Receivable - Trade, Net | 5118.6 | 5328.7 | 5548.3 | 5161.4 | 4839 |
| Total Inventory | 2424.7 | 2401.9 | 2412.2 | 2218.5 | 1991.5 |
| Prepaid Expenses | 406.2 | 411.2 | 446.4 | 583.6 | 424.9 |
| Other Current Assets, Total | |||||
| Total Assets | 30059.9 | 29214.5 | 27677.8 | 27205.8 | 26348.7 |
| Property/Plant/Equipment, Total - Net | 3880.9 | 3763 | 3704.2 | 3637.7 | 3556.4 |
| Long Term Investments | 6114.9 | 6640.1 | 6016.9 | 6463.2 | 7130.7 |
| Other Long Term Assets, Total | 2226.2 | 2011.8 | 1724 | 1575 | 1355.6 |
| Total Current Liabilities | 3100.1 | 3141.3 | 2879.2 | 3033.9 | 3007.6 |
| Accounts Payable | 599.5 | 589.2 | 535.6 | 534.2 | 470.3 |
| Accrued Expenses | 2074.3 | 2074.2 | 1796.4 | 1933.4 | 2046 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0 | 0 | 0 | |
| Other Current Liabilities, Total | 426.3 | 477.9 | 547.2 | 566.3 | 491.3 |
| Total Liabilities | 6564.7 | 6550.5 | 6239 | 6518 | 6434 |
| Total Long Term Debt | 2701.8 | 2701.4 | 2701.1 | 2700.7 | 2700.4 |
| Long Term Debt | 1981.8 | 1981.4 | 1981.1 | 1980.7 | 1980.4 |
| Capital Lease Obligations | 720 | 720 | 720 | 720 | 720 |
| Other Liabilities, Total | 762.8 | 707.8 | 658.7 | 783.4 | 726 |
| Total Equity | 23495.2 | 22664 | 21438.8 | 20687.8 | 19914.7 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0 | 0.1 | 0.1 | 0.1 | 0.1 |
| Additional Paid-In Capital | 10597.7 | 9949.3 | 9518.2 | 9120.2 | 8754.1 |
| Retained Earnings (Accumulated Deficit) | 24124.5 | 23306.7 | 22109.6 | 20793.9 | 19941.8 |
| Treasury Stock - Common | -11045.5 | -10353.3 | -9914 | -9002.6 | -8611.2 |
| Other Equity, Total | -181.5 | -238.8 | -275.1 | -223.8 | -170.1 |
| Total Liabilities & Shareholders’ Equity | 30059.9 | 29214.5 | 27677.8 | 27205.8 | 26348.7 |
| Total Common Shares Outstanding | 109.7 | 109.6 | 108.8 | 109.5 | 109.507 |
| Intangibles, Net | 928.7 | 915.5 | 804.1 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 4338.4 | 8075.3 | 3513.2 | 2115.8 | 2444.4 |
| Cash From Operating Activities | 5014.9 | 7081.3 | 2618.1 | 2430 | 2195.1 |
| Cash From Operating Activities | 341.4 | 286.2 | 235.9 | 210.3 | 148.2 |
| Deferred Taxes | -746.4 | -147.1 | 75.6 | -130.6 | -140 |
| Non-Cash Items | 1324.8 | 783.4 | 297 | 435 | 439.5 |
| Cash Taxes Paid | 1502.4 | 1218.4 | 188.1 | 342.3 | 205.6 |
| Cash Interest Paid | 53.7 | 55.8 | 23.2 | 25 | 22.3 |
| Changes in Working Capital | -243.3 | -1916.5 | -1503.6 | -200.5 | -697 |
| Cash From Investing Activities | -3784.6 | -5384.7 | -70.6 | -2027.8 | -1463 |
| Capital Expenditures | -1616.9 | -551.9 | -614.6 | -429.6 | -383.1 |
| Other Investing Cash Flow Items, Total | -2167.7 | -4832.8 | 544 | -1598.2 | -1079.9 |
| Cash From Financing Activities | -1009 | -1005.8 | -1970.5 | -252.1 | -77.1 |
| Financing Cash Flow Items | -445.7 | -1032.7 | -680.8 | -188 | -187.2 |
| Issuance (Retirement) of Stock, Net | -563.3 | 26.9 | -3271.6 | -64.1 | 110.1 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 1981.9 | 0 | |
| Net Change in Cash | 221.3 | 690.8 | 577 | 150.1 | 655 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 817.8 | 4338.4 | 3141.3 | 1825.6 | 973.5 |
| Cash From Operating Activities | 1367.6 | 5014.9 | 3295 | 2666.1 | 2101.7 |
| Cash From Operating Activities | 99.5 | 341.4 | 241.3 | 148.7 | 74.3 |
| Deferred Taxes | -216.5 | -746.4 | -466.7 | -381 | -225 |
| Non-Cash Items | 425.9 | 1324.8 | 1004.4 | 1030.9 | 455.7 |
| Changes in Working Capital | 240.9 | -243.3 | -625.3 | 41.9 | 823.2 |
| Cash From Investing Activities | -235.7 | -3784.6 | -1926.9 | -2119.2 | -1705.3 |
| Capital Expenditures | -279.1 | -1616.9 | -1364.7 | -295.4 | -141.8 |
| Other Investing Cash Flow Items, Total | 43.4 | -2167.7 | -562.2 | -1823.8 | -1563.5 |
| Cash From Financing Activities | -322.5 | -1009 | -761.4 | -36.4 | 64.7 |
| Financing Cash Flow Items | -97 | -445.7 | -256.6 | -147.7 | -98.8 |
| Issuance (Retirement) of Stock, Net | -225.5 | -563.3 | -504.8 | 111.3 | 163.5 |
| Net Change in Cash | 809.4 | 221.3 | 606.7 | 510.5 | 461.1 |
| Issuance (Retirement) of Debt, Net | 0 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Fidelity Management & Research Company LLC | Investment Advisor | 8.4629 | 9130793 | -1527454 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.1573 | 8801136 | 130059 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.619 | 6062473 | -94658 | 2023-03-31 | LOW |
| Capital World Investors | Investment Advisor | 5.4041 | 5830586 | -411849 | 2023-03-31 | LOW |
| JP Morgan Asset Management | Investment Advisor | 4.5503 | 4909415 | 156161 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.5357 | 4893616 | -67269 | 2023-03-31 | LOW |
| Dodge & Cox | Investment Advisor/Hedge Fund | 2.2103 | 2384701 | 161642 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 2.0558 | 2217993 | 10003 | 2023-03-31 | LOW |
| Capital International Investors | Investment Advisor | 1.9959 | 2153472 | 623529 | 2023-03-31 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 1.8837 | 2032374 | 449576 | 2023-03-31 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 1.6386 | 1767919 | -648328 | 2023-03-31 | LOW |
| Invesco Capital Management (QQQ Trust) | Investment Advisor | 1.3154 | 1419159 | 5544 | 2023-04-30 | LOW |
| Loomis, Sayles & Company, L.P. | Investment Advisor/Hedge Fund | 1.2164 | 1312407 | -25274 | 2023-03-31 | LOW |
| Yancopoulos (George D) | Individual Investor | 1.133 | 1222370 | -16824 | 2023-04-11 | LOW |
| Putnam Investment Management, L.L.C. | Investment Advisor/Hedge Fund | 1.0801 | 1165317 | 47784 | 2023-03-31 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.8958 | 966467 | -21169 | 2022-12-31 | LOW |
| American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 0.8914 | 961710 | -140292 | 2023-03-31 | LOW |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.787 | 849127 | 17758 | 2023-03-31 | LOW |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.7663 | 826791 | 129091 | 2023-03-31 | LOW |
| BlackRock Asset Management Ireland Limited | Investment Advisor | 0.7598 | 819779 | -39423 | 2023-03-31 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group530K+
Traders
87K+
Active clients monthly
$46M+
Monthly investing volume
$31M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Regeneron Company profile
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.| Industry: | Bio Therapeutic Drugs |
777 Old Saw Mill River Road
TARRYTOWN
NEW YORK 10591
US
Income Statement
- Annual
- Quarterly
News
USD forecast: DXY slides in risk-off market sentiment
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
16:10, 24 May 2023
Oil price forecast: Will WTI and Brent regain momentum in 2023?
Discover the drivers behind Brent and WTI volatility and get insights from analyst predictions.
11:38, 22 May 2023
Weekly Roundup: Tech stocks lead the way
US stocks push higher as risk appetite surges despite the uncertainty
13:39, 19 May 2023
USD/JPY continues to build higher towards 138
USD/JPY advances towards the top of its ascending triangle as the US dollar moves higher
11:50, 17 May 2023
Gold price predictions for next 5 years: Will gold continue rising?
The yellow metal reached near record-highs, yet will it maintain the momentum and for how long?
07:50, 17 May 2023
Gold price forecast: Will gold surpass record highs?
The US debt ceiling concerns and the banking crisis have been favourable for gold, yet is there more upside potential?
12:52, 16 May 2023
Top AI stocks: What companies are leading the AI revolution?
Unravel key AI market leaders and their latest products, key AI industry trends and forecasts.
14:55, 15 May 2023People also watch
Still looking for a broker you can trust?
Join the 530.000+ traders worldwide that chose to trade with Capital.com